NSCLC & Targeted Therapy: A Brief Overview and Update in the Metastatic Setting

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

NSCLC & Targeted Therapy: A Brief Overview and Update in the Metastatic Setting

By Memorial Sloan Kettering Cancer Center FEATURING Michael Hwang

0 views

December 13, 2023

Disclaimer: On March 1, 2024, The FDA has approved amivantamab-vmjw (RYBREVANT®) plus carboplatin and pemetrexed for the frontline treatment of patients with locally advanced or mNSCLC harboring EGFR exon 20 insertion mutations, as detected by an FDA-approved test.

Comments 0